Nobody could have known back then that Aib would one day become a central molecular innovation in semaglutide, the GLP-1 agonist at the heart of Ozempic and Wegovy, both now considered among the most revolutionary drugs of all time, ones that can significantly shape the future of not just medicine but the entire economy of public health
Finally, formulation qualitystability of the peptide, correct reconstitution, and storagecan alter how much active drug you actually deliver, subtly affecting both the duration and intensity of response
GLP-1s, Ozempic, Wegovy, and Mounjaro, are changing how many people eat
Medical College, and Hospital, Ambajogai
While a patient can stop semaglutide, it has been generally touted as a long-term treatment option for chronic disease management
Beyond these methodological and biological challenges, several core evidence gaps deserve emphasis